Observation on the Effect of Yisui Granules Combined with Methylprednisolone Sodium Succinate in the Treatment of Acute Multiple Sclerosis
Objective:To investigate the effect of Yisui Granules combined with Methylprednisolone Sodium Succinate in the treatment of acute multiple sclerosis(MS).Method:A total of 62 patients with acute MS treated in First People's Hospital of Tianshui from January 2022 to July 2023 were selected and divided into control group(given Methylprednisolone Sodium Succinate)and observation group(combined with Yisui Granules)by random number table method,with 31 cases in each group.The extended disability status scale(EDSS),inflammatory factors,neurofactors,serum T lymphocyte subsets and cerebrospinal fluid T lymphocyte subsets were compared between the two groups.Result:After treatment,the EDSS scores were decreased in both groups,and that in the observation group was lower than that in the control group,the differences were statistically significant(P<0.05).After treatment,interferon-γ(IFN-γ)and matrix metalloproteinase-9(MMP-9)were decreased in both groups,interleukin-12p40(IL-12p40)were increased in both groups,and IFN-γ and MMP-9 in observation group were lower than those in control group,IL-12p40 was higher than that in control group,the differences were statistically significant(P<0.05).After treatment,transforming growth factor-β1(TGF-β1)were increased in both groups,S-100 protein and Tau protein were decreased in both groups,and TGF-β1 in observation group was higher than that in control group,S-100 protein and Tau protein were lower than those in control group,the differences were statistically significant(P<0.05).After treatment,serum CD4+and CD8+were increased in both groups,and CD4+/CD8+were decreased,the differences were statistically significant(P<0.05).After treatment,cerebrospinal fluid CD4+and CD4+/CD8+were decreased in both groups,and CD8+were increased,the differences were statistically significant(P<0.05).Conclusion:Yisui Granules combined with Methylprednisolone Sodium Succinate in the treatment of acute MS can reduce inflammatory factors,improve nerve function,regulate neurofactors and T lymphocyte subsets,and delay immune response.
万方数据
维普
